TRIZIVIR Drug Patent Profile

Which patents cover Trizivir, and when can generic versions of Trizivir launch?

Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Summary for TRIZIVIR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	20
Drug Prices:	Drug price information for TRIZIVIR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIZIVIR
What excipients (inactive ingredients) are in TRIZIVIR?	TRIZIVIR excipients list
DailyMed Link:	TRIZIVIR at DailyMed

See drug prices for TRIZIVIR

Recent Clinical Trials for TRIZIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
AIDS Clinical Trials Group	Phase 3
Ines Perez	Phase 4

See all TRIZIVIR clinical trials

Paragraph IV (Patent) Challenges for TRIZIVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIZIVIR	Tablets	abacavir sulfate; lamivudine; zidovudine	300 mg/150 mg/ 300 mg	021205	1	2011-03-22

US Patents and Regulatory Information for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000		DISCN	Yes	No

Expired US Patents for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000

International Patents for TRIZIVIR

When does loss-of-exclusivity occur for TRIZIVIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIZIVIR around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	11	Antiviral nucleosides.
African Regional IP Organization (ARIPO)	8600027
African Regional IP Organization (ARIPO)	8600044

Supplementary Protection Certificates for TRIZIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
0382526	96C0035	Belgium		PRODUCT NAME: LAMIVUDINE; NAT. REGISTRATION NO/DATE: EU/1/96/015/001 19960808; FIRST REGISTRATION: CH 53 662 013 19960228
0382526	C960025	Netherlands		PRODUCT NAME: LAMIVUDINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/015/001 - EU/1/96/015/002 19960808

Trizivir (abacavir/lamivudine/zidovudine) Market Dynamics and Financial Trajectory (Global and Key Jurisdictions)

Last updated: July 29, 2026

Trizivir’s commercial profile is shaped by (1) long-established HIV antiretroviral competition, (2) a shrinking addressable pool as treatment guidelines shift toward integrase-inhibitor based regimens, and (3) genericization pressure in multiple markets. In practice, Trizivir remains a niche, low-growth or declining brand compared with modern single-tablet regimens and newer fixed-dose combinations.

---

Why did Trizivir lose share as HIV treatment standards changed?

What HIV regimens replaced Trizivir in routine care?

Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs): abacavir, lamivudine, and zidovudine. Over time, HIV treatment shifted toward regimens built around integrase strand transfer inhibitors (INSTIs) and higher genetic-barrier combinations, which generally offer faster viral suppression, improved tolerability, and simpler dosing than older NRTI-heavy combinations.

Share pressure mechanism

• Newer regimens reduced the need for zidovudine and other older NRTI backbones.
• Fixed-dose “single-tablet” options improved adherence and simplified switching.
• Clinician preference moved toward regimens with better long-term tolerability profiles.

Does Trizivir still have a meaningful patient pool?

Trizivir remains used in selected scenarios, typically when patients are stable on an older regimen, have limited options due to resistance/tolerability, or require a fixed-dose three-NRTI structure for a specific clinical reason. That keeps Trizivir in the market, but as a declining niche rather than a growth driver.

---

How strong is Trizivir pricing power versus generic competition?

What is the impact of generic abacavir/lamivudine/zidovudine on brand economics?

Trizivir’s brand economics are highly sensitive to:

• Availability of multi-component generics (abacavir + lamivudine + zidovudine) in fixed-dose or interchangeable pill combinations.
• Competitive pricing from manufacturers in EU5, Canada, and other markets where generics dominate.
• Payer formulary status that shifts toward lowest-cost alternatives.

Commercial effect

• Brand-to-generic substitution usually compresses net pricing to a fraction of peak levels.
• Even when Trizivir retains formulary listing for clinical continuity, budget pressure drives down gross-to-net.

What pricing model usually governs older HIV fixed-dose brands?

For legacy antiretrovirals, pricing tends to follow a stepped pattern:

1. Brand launch and protected period.
2. Generic entry in multiple dosage forms.
3. Tendering and payer net price erosion.
4. Continued use for stable patients but limited new starts.

This dynamic suppresses revenue CAGR and raises marketing spend-to-revenue ratios.

---

What is Trizivir’s revenue trajectory since patent and exclusivity erosion?

What financial trajectory is typical for established HIV fixed-dose combinations?

For older HIV combination products like Trizivir, the observed industry trajectory generally tracks:

• Early high adoption, then maturity.
• Stabilization once guidelines mature.
• Gradual decline as younger patients start with INSTI-based regimens.
• Further erosion after genericization and increased reimbursement pressure.

Business implication

• Revenue declines tend to be persistent unless the product retains a uniquely positioned clinical niche with strong payer support, which is less common for older NRTI fixed-dose products.

What drives year-to-year volatility?

Volatility tends to come from:

• Formulary changes by national health systems and large purchasers.
• Temporary supply shocks or manufacturing disruptions at generic suppliers.
• Category-wide switching programs (e.g., moving stable patients from older backbones).
• Currency effects and tender price resets.

---

Which competitors most directly affect Trizivir in the fixed-dose HIV market?

How does Trizivir compare with modern single-tablet regimens?

Clinically, Trizivir competes not only with fixed-dose combinations containing abacavir and lamivudine, but also with the broad class of INSTI-based single-tablet regimens that have become first-line standard.

Competitive set characteristics

• Single-tablet convenience (once-daily regimens).
• Higher perceived long-term tolerability.
• Strong guideline alignment for first-line therapy.

Where is substitution most likely?

Substitution tends to be strongest in:

• Treatment-naïve initiations (largest inflow).
• Patients eligible for guideline-concordant regimens with lower pill burden.
• Payer-driven switches that prioritize lower-cost, guideline-standard formulations.

---

What do FDA and Orange Book status indicate for generic entry risk in the US?

What is the Orange Book status of Trizivir?

Trizivir’s US exclusivity and patent protection determine whether generic abacavir/lamivudine/zidovudine tablets face delayed entry. The practical expectation for older NRTI fixed-dose products is that patents have largely expired and generic entry can occur through ANDA pathways once listed protections are cleared.

What is the generic entry risk profile?

For legacy fixed-dose products:

• After expiration of composition-of-matter and formulation patents, additional patent thickets tend to have limited effect on ANDA entry timing.
• Remaining delay often comes from specific method-of-use or formulation patents, if any remain unexpired at the relevant time.

Commercial effect

• Risk of further erosion is persistent because even if the brand survives on formulary, generics cap net pricing.

(Note: This analysis requires current Orange Book listings and expiration data for Trizivir-specific patents to be fully precise. No jurisdiction-specific patent listing can be validated here without access to up-to-date Orange Book records.)

---

How do formulation and method-of-use patents usually affect Trizivir’s competitive landscape?

What patent types tend to matter for HIV fixed-dose tablets?

For fixed-dose combination tablets, key patent layers typically include:

• Composition-of-matter for each API and specific combination claims.
• Fixed-dose formulation patents tied to ratios, excipients, or dissolution properties.
• Method-of-use patents related to dosing, patient selection, or treatment strategies.

Does patent estate strength typically drive revenue for legacy HIV products?

For older products already commercialized for years, patent estate strength typically matters less than:

• Guideline displacement by newer drug classes.
• Generic availability and payer procurement structures.
• Patient switching patterns for stable disease.

Practical result

• Patent-driven exclusivity rarely restores long-term brand growth once clinical standards shift.

---

What litigation and settlement patterns matter for Trizivir?

How do Paragraph IV disputes typically affect legacy HIV brands?

Where generic applicants challenge patents under Paragraph IV:

• Settlements can delay entry for a defined period.
• Litigation duration can create temporary revenue protection.
• If early settlements occur, brand revenue often shows modest bump then resumes decline.

Is litigation the main driver of Trizivir revenue changes?

For widely available older HIV fixed-dose combinations, revenue changes are more commonly dominated by:

• Generic price compression.
• Formulary utilization changes.
• Clinical standard-of-care migration to INSTI regimens.

---

How does Trizivir’s market differ by region?

US versus Europe versus emerging markets

US

• Higher generic utilization and aggressive price competition.
• PBM and formulary constraints drive net price down.

Europe (EU5 and others)

• Tendering systems and centralized purchasing can rapidly shift volumes to lowest-cost suppliers.
• Brand continuity for stable patients can slow decline but not prevent it.

Emerging markets

• Generic adoption may occur faster due to procurement needs and lower tolerance for brand pricing.
• Regulatory and supply chain factors can create uneven market presence.

---

How does Trizivir’s manufacturing and supply chain affect competitiveness?

What matters for fixed-dose generics?

• Bioequivalence compliance across three APIs.
• Scale-up and stability of multi-component tablet formulations.
• Reliable API sourcing for abacavir, lamivudine, and zidovudine.

Commercial effect

• Even if patents do not block entry, manufacturing constraints can delay or limit generic supply, temporarily supporting branded or higher-priced competitors.

---

Key Takeaways

• Trizivir’s growth is structurally constrained by guideline migration from older NRTI-heavy regimens to INSTI-based approaches.
• Genericization and fixed-dose competition compress net pricing, shifting Trizivir to a niche stable-patient segment.
• Revenue trajectory is typically a long decline with limited upside, driven more by payer and formulary economics than by patent tailwinds.
• Competitive risk remains persistent across jurisdictions because multi-API generic entry usually caps brand pricing once exclusivities end.

---

FAQs

1) Is Trizivir still used for treatment-naïve HIV patients?
In most settings, treatment-naïve use is reduced as guideline-preferred INSTI-based regimens dominate; Trizivir use is more common among stable or constrained patients.

2) Does Trizivir compete mainly with other fixed-dose combinations or with INSTI single-tablet regimens?
It competes with both, but substitution risk is highest versus guideline-standard single-tablet INSTI regimens.

3) What is the biggest commercial driver for Trizivir’s net revenue?
Generic pricing and formulary leverage, which compress net prices and reduce volume growth.

4) Do patent expirations still materially affect Trizivir’s market after genericization?
After broad generic availability, incremental patent effects are usually secondary to procurement economics and clinical switching.

5) Where can Trizivir see temporary demand resilience?
Markets where stable-patient continuity policies and formulary inertia slow switching to newer regimens, and where generic supply is constrained.

---

References

1. FDA Orange Book database (Trizivir listings, patent and exclusivity data).
2. US prescribing information and FDA label for Trizivir (abacavir/lamivudine/zidovudine).
3. Updated HIV treatment guideline publications (INSTI-based first-line regimen recommendations).
4. Public drug pricing and reimbursement market reports covering fixed-dose HIV combinations and generic penetration.

(No additional sources are cited here because current Trizivir-specific Orange Book and litigation records were not provided in the input.)